Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
A gene therapy targeting PCSK9 achieved sustained LDL cholesterol reduction in early trials, suggesting a potentially durable approach to cardiovascular risk reduction beyond conventional statin therapy. The durability of genetic intervention raises questions about how to integrate such tools within comprehensive cardiovascular prevention strategies.
Adaptyx has demonstrated the first continuous wearable measurement of free cortisol across multiple days in humans, capturing real-time hormone dynamics rather than isolated snapshots. This shift from point-in-time testing to continuous monitoring addresses a fundamental gap in understanding how cortisol rhythms — not just absolute levels — drive metabolic health, glucose regulation, and stress resilience.
South Korea has officially integrated ring-based cuffless blood pressure monitoring into hypertension treatment guidelines, marking the first regulatory recognition of this technology worldwide. Continuous, non-invasive monitoring addresses a critical gap in detecting masked and nocturnal hypertension—dangerous blood pressure elevations that standard clinic measurements miss.
FibroBiologics has initiated a Phase 1/2 trial of CYWC628, a fibroblast-spheroid cell therapy applied topically to diabetic foot ulcers, enrolling up to 120 patients across Australian sites. The study will assess safety, tolerability, and efficacy compared with standard care alone, with interim analysis at six weeks to evaluate wound healing and safety endpoints.
Longeveron is advancing laromestrocel, an allogeneic mesenchymal stem cell therapy derived from young donor bone marrow, across four clinical indications including hypoplastic left heart syndrome, Alzheimer's disease, pediatric dilated cardiomyopathy, and aging-related frailty. The company's licensing strategy at BIO 2026 signals movement toward commercialization of a cellular therapy platform with demonstrated efficacy signals across multiple disease states.
Axo Longevity will present a data-driven preventive health platform at The Longevity Show 2026 that combines comprehensive biomarker testing, wearable metrics, and AI-powered interpretation to identify physiological changes before they become clinical problems. This represents a shift in longevity medicine from reactive treatment toward continuous monitoring and early signal detection.
Japan's pharmaceutical regulator has signaled support for CardiAMP, a personalized cell therapy that regenerates heart tissue rather than merely managing damage from heart failure. The regulatory consultation record represents a substantive endorsement of regenerative approaches over conventional symptom management for patients with limited treatment options.
Environmental barriers—extreme heat, poor walkability, limited safe spaces—suppress physical activity in low-income older adults, elevating fall risk despite activity's protective effect. The relationship between community design and fall prevention reveals a structural constraint on health optimization that extends beyond individual behavior.
Winona established a research initiative providing funding, mentorship, and resources to early-career clinicians and trainees conducting menopause and women's health research. The program addresses a documented funding gap: women's health research received only 8.8 percent of NIH grant spending between 2013 and 2023, with that share declining over the period.
Fresenius Medical Care launched Kinexus Worldwide, a digital platform enabling remote monitoring, prescription management, and supply ordering for home dialysis patients. The system transmits treatment data to clinics in real time, allowing clinicians to adjust therapy protocols without requiring in-person visits.
Niagen Bioscience renamed its research program to align with company branding while expanding support for NAD+ science across 300+ collaborations and 45+ peer-reviewed human studies. The initiative now prioritizes clinical investigation into energy metabolism, cognitive function, cardiovascular health, and immune response through both oral and pharmaceutical-grade formulations.
Elevated arterial stiffness associates with a distinct CD4+ T cell immune remodeling pattern characterized by increased TCR diversity, chronic activation, and functional impairment—a process mechanistically separate from classical immunosenescence. This CD4+-driven trajectory offers a novel immune signature for identifying subclinical vascular risk before clinical disease emerges.